Unlocking tissue-resolved multiomic biology in blood via tissue-specific extracellular vesicles (TS-EVs)
Mursla Bio has raised $5.0M in total funding. The most recent round was Seed. The last funding was announced in July 2024.
Mursla Bio's investors include TA Ventures, Greater London Authority.
Mursla Bio is headquartered in Cambridge, United Kingdom.
Unlocking tissue-resolved multiomic biology in blood via tissue-specific extracellular vesicles (TS-EVs)
Mursla Bio is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Mursla Bio — Funding & Investors." VCBacked, July 1, 2024, https://www.vcbacked.co/company/mursla-bio. Accessed September 30, 2026.
VCBacked. (2024). Mursla Bio — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/mursla-bio
{{cite web |title=Mursla Bio — Funding & Investors |url=https://www.vcbacked.co/company/mursla-bio |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated